Louise Chen
Stock Analyst at Cantor Fitzgerald
(3.97)
# 666
Out of 4,479 analysts
218
Total ratings
53.98%
Success rate
8.28%
Average return
Main Sectors:
41 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Reiterates: Overweight | $160 | $142.98 | +11.90% | 13 | Jul 1, 2024 | |
| JNJ Johnson & Johnson | Reiterates: Overweight | $215 | $146.03 | +47.23% | 28 | Jul 1, 2024 | |
| PFE Pfizer | Reiterates: Overweight | $45 | $27.83 | +61.70% | 21 | Jun 26, 2024 | |
| LLY Eli Lilly | Reiterates: Overweight | $885 | $906.71 | -2.39% | 37 | Jun 26, 2024 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $17.37 | - | 4 | Jun 25, 2024 | |
| PCVX Vaxcyte | Reiterates: Overweight | n/a | $76.06 | - | 5 | Jun 20, 2024 | |
| MESO Mesoblast | Reiterates: Overweight | n/a | $6.45 | - | 5 | Jun 20, 2024 | |
| LYRA Lyra Therapeutics | Reiterates: Overweight | n/a | $0.28 | - | 2 | Jun 20, 2024 | |
| INVA Innoviva | Reiterates: Overweight | n/a | $16.50 | - | 2 | Jun 20, 2024 | |
| IMVT Immunovant | Reiterates: Overweight | n/a | $26.52 | - | 8 | Jun 20, 2024 | |
| EOLS Evolus | Reiterates: Overweight | n/a | $10.66 | - | 2 | Jun 20, 2024 | |
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $11.93 | - | 5 | Jun 20, 2024 | |
| ATOS Atossa Therapeutics | Reiterates: Overweight | n/a | $1.16 | - | 3 | Jun 20, 2024 | |
| ARDX Ardelyx | Reiterates: Overweight | n/a | $5.28 | - | 4 | Jun 20, 2024 | |
| ANL Adlai Nortye | Reiterates: Overweight | n/a | $3.79 | - | 2 | Jun 20, 2024 | |
| AMRN Amarin Corporation | Reiterates: Overweight | n/a | $0.71 | - | 2 | Jun 20, 2024 | |
| MRK Merck & Co. | Reiterates: Overweight | $155 | $127.72 | +21.36% | 22 | Jun 20, 2024 | |
| ABBV AbbVie | Reiterates: Overweight | $200 | $165.96 | +20.51% | 2 | Jun 20, 2024 | |
| ROIV Roivant Sciences | Reiterates: Overweight | n/a | $10.56 | - | 7 | Jun 18, 2024 | |
| PDSB PDS Biotechnology | Reiterates: Overweight | n/a | $2.95 | - | 2 | May 9, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $925 | $1,044.66 | -11.45% | 1 | Apr 15, 2024 | |
| SPRO Spero Therapeutics | Reiterates: Overweight | n/a | $1.31 | - | 2 | Apr 4, 2024 | |
| SCYX SCYNEXIS | Reiterates: Overweight | n/a | $1.95 | - | 3 | Apr 1, 2024 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | n/a | $4.36 | - | 1 | Apr 1, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Overweight | $65 | $19.78 | +228.61% | 1 | Jan 31, 2024 | |
| ACRS Aclaris Therapeutics | Downgrades: Neutral | n/a | $1.14 | - | 4 | Nov 14, 2023 | |
| CNTB Connect Biopharma Holdings | Reiterates: Overweight | $5 | $1.38 | +262.32% | 2 | Sep 13, 2023 | |
| IMAB I-Mab | Reiterates: Overweight | $25 | $1.58 | +1,482.28% | 4 | Sep 5, 2023 | |
| HCM HUTCHMED (China) | Reiterates: Overweight | $50 | $17.22 | +190.36% | 3 | Sep 5, 2023 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Overweight | $50 | $9.30 | +437.63% | 3 | Aug 22, 2023 | |
| TXMD TherapeuticsMD | Reiterates: Neutral | $5 | $1.66 | +201.20% | 4 | Aug 17, 2023 | |
| VYNE VYNE Therapeutics | Maintains: Overweight | $5 → $9 | $1.81 | +397.24% | 1 | May 12, 2023 | |
| CUTR Cutera | Maintains: Neutral | $33 → $21 | $1.35 | +1,455.56% | 3 | May 10, 2023 | |
| EFTR eFFECTOR Therapeutics | Initiates: Overweight | $1,250 | $0.18 | +694,344.44% | 1 | Sep 13, 2021 | |
| JAGX Jaguar Health | Initiates: Overweight | $67,500 | $3.41 | +1,979,372.14% | 1 | Jul 7, 2021 | |
| FDS FactSet Research Systems | Maintains: Neutral | n/a | $416.01 | - | 1 | Mar 27, 2020 | |
| TEVA Teva Pharmaceutical | Maintains: Neutral | n/a | $16.55 | - | 2 | Feb 12, 2020 | |
| HRTX Heron Therapeutics | Maintains: Overweight | n/a | $2.74 | - | 1 | Jul 19, 2018 | |
| OPK OPKO Health | Initiates: Overweight | n/a | $1.21 | - | 2 | Aug 18, 2017 | |
| RVNC Revance Therapeutics | Initiates: Overweight | n/a | $2.42 | - | 1 | Jul 21, 2017 | |
| DERM Journey Medical | Initiates: Overweight | n/a | $5.24 | - | 1 | Jun 22, 2017 |
Novo Nordisk
Jul 1, 2024
Reiterates: Overweight
Price Target: $160
Current: $142.98
Upside: +11.90%
Johnson & Johnson
Jul 1, 2024
Reiterates: Overweight
Price Target: $215
Current: $146.03
Upside: +47.23%
Pfizer
Jun 26, 2024
Reiterates: Overweight
Price Target: $45
Current: $27.83
Upside: +61.70%
Eli Lilly
Jun 26, 2024
Reiterates: Overweight
Price Target: $885
Current: $906.71
Upside: -2.39%
Zai Lab
Jun 25, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.37
Upside: -
Vaxcyte
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $76.06
Upside: -
Mesoblast
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.45
Upside: -
Lyra Therapeutics
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.28
Upside: -
Innoviva
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.50
Upside: -
Immunovant
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.52
Upside: -
Evolus
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.66
Upside: -
Cidara Therapeutics
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.93
Upside: -
Atossa Therapeutics
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.16
Upside: -
Ardelyx
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.28
Upside: -
Adlai Nortye
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.79
Upside: -
Amarin Corporation
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.71
Upside: -
Merck & Co.
Jun 20, 2024
Reiterates: Overweight
Price Target: $155
Current: $127.72
Upside: +21.36%
AbbVie
Jun 20, 2024
Reiterates: Overweight
Price Target: $200
Current: $165.96
Upside: +20.51%
Roivant Sciences
Jun 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.56
Upside: -
PDS Biotechnology
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.95
Upside: -
Regeneron Pharmaceuticals
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $1,044.66
Upside: -11.45%
Spero Therapeutics
Apr 4, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.31
Upside: -
SCYNEXIS
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.95
Upside: -
Zevra Therapeutics
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.36
Upside: -
Rocket Pharmaceuticals
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $19.78
Upside: +228.61%
Aclaris Therapeutics
Nov 14, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.14
Upside: -
Connect Biopharma Holdings
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $1.38
Upside: +262.32%
I-Mab
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $1.58
Upside: +1,482.28%
HUTCHMED (China)
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $17.22
Upside: +190.36%
Arcutis Biotherapeutics
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $9.30
Upside: +437.63%
TherapeuticsMD
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.66
Upside: +201.20%
VYNE Therapeutics
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $1.81
Upside: +397.24%
Cutera
May 10, 2023
Maintains: Neutral
Price Target: $33 → $21
Current: $1.35
Upside: +1,455.56%
eFFECTOR Therapeutics
Sep 13, 2021
Initiates: Overweight
Price Target: $1,250
Current: $0.18
Upside: +694,344.44%
Jaguar Health
Jul 7, 2021
Initiates: Overweight
Price Target: $67,500
Current: $3.41
Upside: +1,979,372.14%
FactSet Research Systems
Mar 27, 2020
Maintains: Neutral
Price Target: n/a
Current: $416.01
Upside: -
Teva Pharmaceutical
Feb 12, 2020
Maintains: Neutral
Price Target: n/a
Current: $16.55
Upside: -
Heron Therapeutics
Jul 19, 2018
Maintains: Overweight
Price Target: n/a
Current: $2.74
Upside: -
OPKO Health
Aug 18, 2017
Initiates: Overweight
Price Target: n/a
Current: $1.21
Upside: -
Revance Therapeutics
Jul 21, 2017
Initiates: Overweight
Price Target: n/a
Current: $2.42
Upside: -
Journey Medical
Jun 22, 2017
Initiates: Overweight
Price Target: n/a
Current: $5.24
Upside: -